Clinical trial · no report yet · Phase 2
PCR-MIB
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
- NCT02662062 ↗
- Completed
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab; Cisplatin; Radiotherapy
- Arms
- Pembrolizumab · Experimental
- Enrollment
- 28
- Primary outcomes
- The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group with Peter MacCallum Cancer Centre, Australia
- Start
- Jul 11, 2017
- Primary completion
- May 12, 2022
- Results posted
- Yes
- Registry record
- NCT02662062 · updated Jan 27, 2025
Publications
linked from the registry- Weickhardt A, Foroudi F, Lawrentschuk N, Xie J, Sidhom M, Pal A, Grimison P, Zhang A, Ng S, Tang C, Hovey E, Chen C, Hruby G, Guminski A, McJannett M, Conduit C, Tran B, Davis ID, Hayne D. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502). Eur Urol Oncol. 2024 Jun;7(3):469-477. doi: 10.1016/j.euo.2023.09.011. Epub 2023 Oct 7. PubMed 37806844